Human Pancreatic Lipase Measurement Using pH-Adjusted Bile Acids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring human pancreatic lipase activity using diglyceride substrates are influenced by non-pancreatic lipases like lipoprotein lipase or hepatic lipase, leading to reduced specificity and reproducibility.
Innovation Solution
Adjusting the pH to 7.4 or lower and using specific conjugated or non-conjugated bile acids, such as glycodeoxycholic acid or deoxycholic acid, in combination with colipase to maximize human pancreatic lipase activity while minimizing the influence of non-pancreatic lipases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a diglyceride substrate is used to measure human pancreatic lipase activity, then the measurement can be performed with clear substrate solution, but the measurement is influenced by non-pancreatic lipases such as lipoprotein lipase or hepatic lipase, reducing specificity
Solution Approach 1:
The patent changes the pH parameter of the measurement system to 7.4 or lower, which selectively inhibits non-pancreatic lipases while maintaining pancreatic lipase activity. This parameter change resolves the contradiction by allowing clear substrate solution usage while improving specificity through pH-dependent enzyme selectivity.
2Measurement precision
If the pH is adjusted to 7.4 or lower to reduce non-pancreatic lipase influence, then specificity improves, but the measurement must be performed under more controlled acidic conditions
Solution Approach 1:
The patent establishes a specific pH range (7.4 or lower) as the optimal condition for measuring human pancreatic lipase activity with reduced non-pancreatic lipase interference. By defining this parameter threshold, the patent simplifies the control requirement while maintaining high specificity, rather than requiring complex dynamic pH control.
3Ease of manufacture
If conventional triglyceride emulsion is used as substrate, then the measurement can be performed, but phase separation occurs during storage and reproducibility is reduced
Solution Approach 1:
The patent changes the substrate from triglyceride emulsion to diglyceride, which has different physical properties that prevent phase separation during storage. This parameter change in substrate type maintains ease of preparation while significantly improving reliability and reproducibility of measurements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the specificity and reproducibility of human pancreatic lipase activity measurements by reducing the impact of non-pancreatic lipases, allowing for more accurate detection of pancreatic lipase activity in samples.
Implementation Method 1
a bile acid that makes a pH for giving a maximum value of the human pancreatic lipase activity to be lower than 7.7
Implementation Method 2
the conformation of the human pancreatic lipase is changed if the colipase is additionally present, and the active center of the human pancreatic lipase can bound to a substrate
Implementation Method 3
a triglyceride is conventionally used as the substrate. The triglyceride is used in the form of what is called an emulsion in which it is emulsified and dispersed in a buffer solution
Data Source
AI summary
A measurement method for human pancreatic lipase activity in a sample, includes bringing a bile acid that makes a pH for giving a maximum value of human pancreatic lipase activity to be lower than 7.7, a diglyceride and a colipase into contact with the sample at pH 7.4 or lower; and detecting a signal amount varying in accordance with the human pancreatic lipase activity in the sample, and the bile acid is a bile acid containing: one of or two or more of a-type bile acids selected from the group consisting of GDCA, GCDCA, TDCA, TCDCA and salts thereof; and/or a combination of one of or two or more of b-1-type bile acids selected from the group consisting of GCA, GUDCA, TCA, TUDCA and salts thereof, and one of or two or more of b-2-type bile acids selected from the group consisting of DCA, CDCA and salts thereof.